Goodbye, Dolly: Rejecting Cloned Food
By Dr. Allan Kornberg,
Business Week
| 02. 21. 2007
Ten years after scientists produced the first clone of a mammal, a sheep named Dolly, the U.S. Food and Drug Administration has issued a draft assessment that moves our nation closer to the widespread sale of meat and dairy products from animal clones.
During the next two months, Americans have the opportunity to comment on the FDA's draft and influence whether or not food from animal clones ends up in our fast food and on our supermarket shelves. Debate is under way on the possible long-term risk to human health, consumer choice, and religious and ethical concerns. The one group that stands to lose the most if the FDA's assessment is accepted is the farm animals that will suffer and die to produce food and dairy products that most Americans don't want to eat. Since animals cannot speak, those of us who care about animal welfare must speak out for them.
"Unconscionable"
Over the past decade, news of Dolly's birth and subsequent announcements that scientists succeeded in producing clones of cows, pigs, goats, and other animals—even cats and dogs—have been...
Related Articles
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Patrick Foong, BioNews | 11.03.2025
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...